. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: Pediatr Blood Cancer. 2010 Aug;55(2):248–253. doi: 10.1002/pbc.22519

Table III.

Outcomes of Therapy According to Genotype.

2941/2961 de novo	g/g		t/g		t/t		g/g vs t/g vs t/t
	N	% ± 2SE%	N	% ± 2SE%	N	% ± 2SE%	p
5yr OS from study entry	91	57 ± 10	183	46 ± 8	184	52 ± 8	0.421
5yr EFS from study entry	91	45 ± 10	183	36 ± 7	184	43 ± 7	0.472
5yr OS from end of course 1	72	63 ± 12	150	51 ± 8	135	63 ± 8	0.220
5yr DFS from end of course 1	72	54 ± 12	150	41 ± 8	135	52 ± 9	0.124
5yr RR from end of course 1	72	30 ± 11	150	45 ± 8	135	38 ± 9	0.126
5yr TRM from end of course 1	72	16 ± 9	150	14 ± 6	135	10 ± 5	0.614
5yr OS from end of course 2	58	67 ± 12	130	55 ± 9	122	67 ± 9	0.249
5yr DFS from end of course 2	58	58 ± 13	130	45 ± 9	122	56 ± 9	0.131
5yr RR from end of course 2	58	32 ± 12	130	47 ± 9	122	40 ± 9	0.126
5yr TRM from end of course 2	58	10 ± 8	130	8 ± 5	122	5 ± 4	0.389